Study on Dosage Adjustment in Combination Therapy with IFN .ALPHA.-2 b and Ribavirin for Chronic Hepatitis C

EFFICACY AND SAFETY OF COMBINATION THERAPY OF INTERFERON-ALPHA 2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C

Introduction: The aim of this study is to assess the therapeutic efficacy and safety of a particular brand of IFN alpha (PDferon B®) in combination with ribavirin (RlBA) on Iranian patients with chronic hepatitis C (CHC). The addition of RIBA to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monother...

efficacy of alfacalcidol on peg-ifn/ ribavirin combination therapy for elderly patients with chronic hepatitis c: a pilot study

patients and methods consecutive twenty chc patients aged ≥ 65 years were enrolled in this pilot study. fifteen patients met the inclusion criteria and received peg-ifn/ ribavirin therapy combined with alfacalcidol. four-week lead-in of oral alfacalcidol was conducted, and it was subsequently and concurrently administered in peg-ifn/ ribavirin combination therapy (vitamin d group). age, gender,...

efficacy and safety of interferon-alpha (pdferon b®) and ribavirin combination therapy in patients with chronic hepatitis c in iran

Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.

Pulmonary toxicity is a rare but potentially fatal side effect occurring during interferon (IFN) alpha treatment for chronic hepatitis C. We present a 47-year-old woman who had chronic hepatitis C and was treated with pegylated IFN alpha-2b in combination with ribavirin, with a good virological response by week 10 of therapy. Then the patient began to complain of dyspnea on exertion and a dry c...

Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study

BACKGROUND Serum vitamin D concentration is reported to show a decrease in older age. Patients with chronic hepatitis C (CHC) in Japan are older on average than those in Western countries. Moreover, the outcome of pegylated-interferon (PEG-IFN)/ ribavirin therapy combined with vitamin D in elderly patients is unclear. OBJECTIVES This pilot study explored the efficacy and safety of alfacalcido...